Minoxidil and captopril in severe hypertension. 1986

P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter

The antihypertensive efficacy of minoxidil and captopril was compared in 23 males with essential or renal parenchymatous hypertension refractory to conventional antihypertensive drug therapy. Following a pretreatment period the patients were randomly assigned to receive either minoxidil, 2.5 mg twice daily (n = 12), or captopril, 25 mg twice daily (n = 11). In patients with diastolic blood pressure greater than 95 mmHg, doses of minoxidil and captopril were increased in 2-week intervals. Patients who maintained diastolic pressure greater than 95 mmHg and/or those with intolerable side effects were switched over to the alternative substance. After a mean observation period of 12 weeks a significant decrease in systolic and diastolic blood pressure was observed (179/114 vs 148/92 mmHg in the minoxidil group; 176/111 vs 158/97 mmHg in the captopril group). The primary response rate was 75% in patients treated with minoxidil and 55% in those with captopril (not significant). After the change to the alternative substance two of the four non-responders on captopril and one of the two non-responders on minoxidil became responders. Side effects occurred significantly more often during minoxidil than captopril (p less than 0.05). The high efficacy of minoxidil and captopril in the treatment of severe hypertension refractory to conventional drugs was confirmed. Minoxidil lowered blood pressure slightly more than captopril, but it had a higher incidence of side effects than captopril.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008914 Minoxidil A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) Loniten,Regaine,Rogaine,U 10858
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
January 1978, Acta medica Scandinavica,
P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
October 1983, Australian and New Zealand journal of medicine,
P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
November 1978, European journal of clinical pharmacology,
P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
January 1984, Clinical pharmacy,
P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
June 1983, Archives of internal medicine,
P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
January 1981, Drug and therapeutics bulletin,
P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
July 1975, JAMA,
P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
January 1975, Current therapeutic research, clinical and experimental,
P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
March 1981, American journal of diseases of children (1960),
P Greminger, and E Foerster, and H Vetter, and P Baumgart, and W Vetter
March 1978, The Journal of pediatrics,
Copied contents to your clipboard!